109 related articles for article (PubMed ID: 12566755)
1. Circulating inhibin forms in patients with hydatidiform mole.
Kato T; Seki K; Matsui H; Sekiya S
Gynecol Obstet Invest; 2002; 54(2):114-7. PubMed ID: 12566755
[TBL] [Abstract][Full Text] [Related]
2. Inhibin: a new circulating marker of hydatidiform mole?
Yohkaichiya T; Fukaya T; Hoshiai H; Yajima A; de Kretser DM
BMJ; 1989 Jun; 298(6689):1684-6. PubMed ID: 2503176
[TBL] [Abstract][Full Text] [Related]
3. Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta-subunit.
Badonnel Y; Barbé F; Legagneur H; Poncelet E; Schweitzer M
Clin Endocrinol (Oxf); 1994 Aug; 41(2):155-62. PubMed ID: 7523000
[TBL] [Abstract][Full Text] [Related]
4. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of serum inhibin, 17 beta-estradiol and progesterone in cases of hydatidiform mole.
Hegab HM; Schindler AE
Gynecol Endocrinol; 2004 Feb; 18(2):107-13. PubMed ID: 15195503
[TBL] [Abstract][Full Text] [Related]
6. Serum relaxin in patients with hydatidiform mole.
Seki K; Uesato T; Tabei T; Kato K
Obstet Gynecol; 1986 Mar; 67(3):381-3. PubMed ID: 3945450
[TBL] [Abstract][Full Text] [Related]
7. Serum activin A and inhibin A. New clinical markers for hydatidiform mole.
Florio P; Severi FM; Cobellis L; Danero S; Bomè A; Luisi S; Petraglia F
Cancer; 2002 May; 94(10):2618-22. PubMed ID: 12173329
[TBL] [Abstract][Full Text] [Related]
8. Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
Pautier P; Ghione S; Brailly-Tabard S; Lhommé C; Morice P; Bidart JM
Hum Reprod; 2001 Nov; 16(11):2434-7. PubMed ID: 11679534
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease.
Duc HN; van Trommel NE; Sweep FC; Massuger LF; Thomas CM
Int J Biol Markers; 2006; 21(1):45-9. PubMed ID: 16711513
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
van Trommel NE; Sweep FC; Schijf CP; Massuger LF; Thomas CM
Eur J Endocrinol; 2005 Oct; 153(4):565-75. PubMed ID: 16189178
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of early-stage nonhydropic mole for diagnosis of persistent trophoblastic disease.
Miyoshi J; Ohba T; Fukunaga M; Katabuchi H
Obstet Gynecol; 2011 Oct; 118(4):847-53. PubMed ID: 21934448
[TBL] [Abstract][Full Text] [Related]
12. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
13. Measurement of circulating inhibin forms during the establishment of pregnancy.
Illingworth PJ; Groome NP; Duncan WC; Grant V; Tovanabutra S; Baird DT; McNeilly AS
J Clin Endocrinol Metab; 1996 Apr; 81(4):1471-5. PubMed ID: 8636353
[TBL] [Abstract][Full Text] [Related]
14. Measurement of inhibin A and inhibin pro-alphaC in early human pregnancy and their role in the prediction of pregnancy outcome in patients with recurrent pregnancy loss.
Al-Azemi M; Ledger WL; Diejomaoh M; Mousa M; Makhseed M; Omu A
Fertil Steril; 2003 Dec; 80(6):1473-9. PubMed ID: 14667886
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of serum human chorionic gonadotropin ratio, progesterone and inhibin A for expectant management of early pregnancies of unknown location.
Majeed H; Højgaard A; Johannesen P; Ladefoged ML; Forman A; Bor P
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):66-9. PubMed ID: 22921576
[TBL] [Abstract][Full Text] [Related]
16. Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy.
Van Trommel NE; Sweep FC; Ross HA; Massuger LF; Thomas CM
Int J Mol Med; 2006 Oct; 18(4):705-11. PubMed ID: 16964426
[TBL] [Abstract][Full Text] [Related]
17. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
[TBL] [Abstract][Full Text] [Related]
18. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
[TBL] [Abstract][Full Text] [Related]
19. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
20. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
